Merck, Lilly, Pfizer top $1B doc-payments list

Tracy Staton Drugmakers forked over more than $ 1 billion to doctors last year, significantly more than reported in 2011. And that's only the amounts we know about. According to ...

Pfizer offers share exchange to grant Zoetis its freedom

Tracy Staton Pfizer is cutting the apron strings at Zoetis. Just months after its highly successful IPO, in which Pfizer sold off a 20% stake, the animal health business is set to become ...

Pfizer picks up the pieces after its armed antibody crashes in PhIII

John Carroll Pfizer says inotuzumab failed a Phase III study for aggressive CD22+ non-Hodgkin lymphoma. The monitoring committee concluded that inotuzumab in combination with rituximab ...

JVs like Pfizer, Hisun hookup provide Chinese companies shot at Western markets

Eric Palmer Joint ventures with Chinese companies have been seen as a way for Big Pharma to get better traction in the exploding China market. But it is not a one-way street. Chinese ...

Johnson & Johnson, Pfizer target painkiller revivals as FDA warms to abuse deterrents

Ryan McBride The FDA has fueled a pharmaceutical arms race in the painkiller market with the agency's decision last month to bar the sale and production of generic OxyContin, which ...

Pfizer combats online fakes with direct-to-patient Viagra sales

Tracy Staton Pfizer ($ PFE) is testing the online-sales waters with a new program to sell Viagra directly to consumers. It's a natural choice: Makers of erectile ...

Pfizer cuts forecast as Q1 sales fall $550M short of estimates

Tracy Staton Like many of its rivals, Pfizer ($ PFE) reported a dip in quarterly sales: 9%, to be exact, to $ 13.5 billion. But worse for Pfizer, the decline was bigger than analysts ...

Giants team on diabetes as Merck partners with Pfizer on SGLT2 combo

John Carroll Jockeying for a leading position in the high-stakes race to develop a new generation of blockbuster diabetes drugs, Merck ($ MRK) is hitching a ride with Pfizer’s ...

Pfizer appealing CHMP ruling on RA treatment Xeljanz

Eric Palmer Pfizer has big expectations for its oral rheumatoid arthritis treatment Xeljanz–about $ 3 billion worth. But those expectations were struck a serious blow when European ...

Pfizer breast cancer hopeful nabs FDA’s ‘breakthrough’ label

Tracy Staton Pfizer ($ PFE) won coveted "breakthrough" status from the FDA for its experimental breast cancer drug palbociclib after impressive interim results from a mid-stage ...

Pfizer to move hundreds of workers to heart of Boston-area R&D hub

Ryan McBride There's Cambridge, and then there's Kendall Square, arguably the heart of all biotech activity in the Boston area. And Pfizer ($ PFE) plans to relocate most of ...

Pfizer cuts physician payments by about $17M in 2012

Eric Palmer It's not that there is no free lunch for doctors, there are just fewer of them.  Some members of Big Pharma are significantly cutting their budgets for spending ...
Page 10 of 11« First...7891011
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS